Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy

Clinical Lung Cancer

Volumn 16, Issue 2, 2015, Pages 128-136

  Wang, Hongmei ^a   Liao, Zhongxing ^b   Zhuang, Yan ^b   Liu, Ying ^a   Levy, Lawrence B ^b   Xu, Ting ^b   Yusuf, Syed Wamique ^b   Gomez, Daniel R ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cardiac medication; Incidental use; Non small cell lung cancer; Radiotherapy; Survival outcome

Indexed keywords

CARDIOVASCULAR AGENT;

ADULT; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT FAILURE;

EID: 84923018322     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.09.006     Document Type: Article

References (46)

1. C.S. Anderson, and W.J. Curran Combined modality therapy for stage III non-small-cell lung cancer Semin Radiat Oncol 20 2010 186 191
2. Vallejo Ocańa C, P. Garrido López, and I. Muguruza Trueba Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions Clin Transl Oncol 13 2011 629 635
3. M.A. van der Drift, H.E. Karim-Kos, and S. Siesling Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years J Thorac Oncol 7 2012 291 298
4. Z.X. Liao, R.R. Komaki, and H.D. Thames Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy Int J Radiat Oncol Biol Phys 76 2010 775 781
5. Y. Oshiro, M. Mizumoto, and T. Okumura Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer J Thorac Oncol 7 2012 370 375
6. J. Willner, K. Baier, E. Caragiani, A. Tschammler, and M. Flentje Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer Int J Radiat Oncol Biol Phys 52 2002 382 389
7. B. Jeremić, B. Miličić, and S. Milisavljevic Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small-cell lung cancer: single institution experience with 600 patients Int J Radiat Oncol Biol Phys 82 2012 1157 1163
8. J.I. Saitoh, Y. Saito, and T. Kazumoto Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study Int J Radiat Oncol Biol Phys 82 2012 1791 1796
9. V. Askoxylakis, J. Dinkel, and M. Eichinger Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial Radiat Oncol 7 2012 157
10. I.E. Naqa, J.O. Deasy, and Y. Mu Datamining approaches for modeling tumor control probability Acta Oncol 49 2010 1363 1373
11. E.R. Velazquez, H.J. Aerts, C. Oberije, D. De Ruysscher, and P. Lambin Prediction of residual metabolic activity after treatment in NSCLC patients Acta Oncol 49 2010 1033 1039
12. K. Kelly, K. Chansky, and L.E. Gaspar Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
13. D. Rades, C. Setter, O. Dahl, S.E. Schild, and F. Noack Fibroblast growth factor 2 - a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 82 2012 442 447
14. A.J. George, W.G. Thomas, and R.D. Hannan The renin-angiotensin system and cancer: old dog, new tricks Nat Rev Cancer 10 2010 745 759
15. J. Wasa, H. Suqiura, E. Kozawa, K. Kohyama, K. Yamada, and O. Taguchi The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model Anticancer Res 31 2011 123 127
16. E. Napoleone, A. Cutrone, and D. Cugino Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells Thromb Res 129 2012 736 742
17. N. Clere, I. Corre, and S. Faure Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis Int J Cancer 127 2010 2279 2291
18. A. Kawabata, A. Baoum, and N. Ohta Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth Cancer Res 72 2012 2057 2067
19. G. Ronquist, G. Frithz, Y.H. Wang, and T. Lindeborg Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer Scand J Urol Nephrol 43 2009 32 36
20. H. Yoshiji, R. Noquchi, and M. Toyohara Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma J Hepatol 51 2009 315 321
21. Y. Nakai, H. Isayama, and H. Ijichi Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine Br J Cancer 103 2010 1644 1648
22. Ú.C. Mc Menamin, L.J. Murray, M.M. Cantwell, and C.M. Hughes Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review Cancer Causes Control 23 2011 221 230
23. Y.K. Chae, M.E. Valsecchi, and J. Kim Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins Cancer Invest 29 2011 585 593
24. K. Yuge, A. Miyajima, and N. Tanaka Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer Ann Surg Oncol 19 2012 3987 3993
25. I. Sipahi, S.M. Debanne, D.Y. Rowland, D.I. Simon, and J.C. Fang Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 2010 624 636
26. S. Bangalore, S. Kumar, and S.E. Kjeldsen Antihypertensive drugs and risk of cancer - network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials Lancet Oncol 12 2011 65 82
27. C. Yoon, H.S. Yang, I. Jeon, Y. Chang, and S.M. Park Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies CMAJ 183 2011 E1073 E1084
28. P.A. Ganz, L.A. Habel, E.K. Weltzien, B.J. Caan, and S.W. Cole Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort Breast Cancer Res Treat 129 2011 549 556
29. S. Wilop, S. von Hobe, M. Crysandt, A. Esser, R. Osieka, and E. Jost Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy J Cancer Res Clin Oncol 135 2009 1429 1435
30. H.M. Wang, Z.X. Liao, and R. Komaki Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy Ann Oncol 24 2013 1312 1319
31. J.Y. Han, S.H. Lee, and N.J. Yoo A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res 17 2011 1553 1560
32. Y.R. van Gestel, S.E. Hoeks, and D.D. Sin COPD and cancer mortality: the influence of statins Thorax 64 2009 963 967
33. C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, and C. La Vecchia Aspirin and cancer risk: a quantitative review to 2011 Ann Oncol 23 2012 1403 1415
34. C. Schroedl, and R. Kalhan Incidence, treatment options, and outcomes of lung cancer in patients with chronic obstructive pulmonary disease Curr Opin Pulm Med 18 2012 131 137
35. P. Hatlen, B.H. Grønberg, A. Langhammer, S.M. Carlsen, and T. Amundsen Prolonged survival in lung cancer patients with diabetes mellitus J Thorac Oncol 6 2011 1810 1817
36. P.E. Gallagher, K. Cook, D. Soto-Pantoja, J. Menon, and E.A. Tallant Angiotensin peptides and lung cancer Curr Cancer Drug Targets 11 2011 394 404
37. G.S. Stergiou, and I.I. Skeva Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor - similarities and differences Curr Top Med Chem 4 2004 473 481
38. M. Fujita, I. Hayashi, S. Yamashina, M. Itoman, and M. Majima Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis Biochem Biophys Res Commun 294 2002 441 447
39. J.H. Neo, C. Malcontenti-Wilson, V. Muralidharan, and C. Christophi Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases J Gastroenterol Hepatol 22 2007 577 584
40. B. Bauvois Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23 2004 317 329
41. A. Melhem-Bertrandt, M. Chavez-Macgregor, and X. Lei Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J Clin Oncol 29 2011 2645 2652
42. S. Holmes, E.J. Griffith, G. Musto, and G.Y. Minuk Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study Cancer Epidemiol 37 2013 881 885
43. H. Maeda Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting Proc Jpn Acad Ser B Phys Biol Sci 88 2012 53 71
44. P.G. Arndt, S.K. Young, and K.R. Poch Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways J Immunol 177 2006 7233 7241
45. G.N. Armaiz-Pena, J.K. Allen, and A. Cruz Src activation by beta-adrenoreceptors is a key switch for tumour metastasis Nat Commun 4 2013 1403
46. E. Fontaine, J. McShane, and R. Page Aspirin and non-small cell lung cancer resections: effect on long-term survival Eur J Cardiothorac Surg 38 2010 21 26